Equities research analysts expect that Cellular Biomedicine Group Inc (NASDAQ:CBMG) will announce earnings of ($0.78) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Cellular Biomedicine Group’s earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.91). Cellular Biomedicine Group posted earnings per share of ($0.45) during the same quarter last year, which suggests a negative year-over-year growth rate of 73.3%. The business is expected to announce its next quarterly earnings results on Tuesday, February 18th.
According to Zacks, analysts expect that Cellular Biomedicine Group will report full-year earnings of ($2.75) per share for the current year, with EPS estimates ranging from ($2.87) to ($2.64). For the next year, analysts forecast that the company will report earnings of ($2.83) per share, with EPS estimates ranging from ($3.12) to ($2.58). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Cellular Biomedicine Group.
Several equities analysts recently weighed in on CBMG shares. Robert W. Baird downgraded Cellular Biomedicine Group from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $26.00 to $19.00 in a research report on Tuesday, November 12th. ValuEngine upgraded Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a report on Friday. BTIG Research initiated coverage on shares of Cellular Biomedicine Group in a research note on Tuesday, September 17th. They set a “buy” rating and a $19.00 price objective for the company. Finally, BidaskClub upgraded shares of Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a report on Wednesday, October 16th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $21.67.
Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Cellular Biomedicine Group by 16.0% in the 2nd quarter. BlackRock Inc. now owns 749,694 shares of the biotechnology company’s stock worth $12,394,000 after buying an additional 103,540 shares during the period. Platinum Investment Management Ltd. increased its stake in Cellular Biomedicine Group by 2.9% during the second quarter. Platinum Investment Management Ltd. now owns 672,885 shares of the biotechnology company’s stock worth $11,123,000 after acquiring an additional 19,170 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Cellular Biomedicine Group by 5.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 557,752 shares of the biotechnology company’s stock worth $8,288,000 after acquiring an additional 29,334 shares during the last quarter. Nikko Asset Management Americas Inc. raised its holdings in shares of Cellular Biomedicine Group by 4.8% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 557,752 shares of the biotechnology company’s stock worth $8,288,000 after purchasing an additional 25,434 shares during the period. Finally, ARK Investment Management LLC raised its holdings in shares of Cellular Biomedicine Group by 10.0% in the 2nd quarter. ARK Investment Management LLC now owns 314,378 shares of the biotechnology company’s stock worth $5,197,000 after purchasing an additional 28,616 shares during the period. Institutional investors and hedge funds own 22.02% of the company’s stock.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
Featured Story: What is the definition of market timing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.